We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Studies set to assess pamrevlumab in IPF have been ...
A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and ...
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID 1) and deupirfenidone 825 mg TID and successfully demonstrated ...
Please provide your email address to receive an email when new articles are posted on . Three differing doses of ISM001-055 were assessed against placebo. Each was “well-tolerated.” Each group also ...
A 2% decline in FVC or DLco significantly increases the risk of death or lung transplant in IPF patients, challenging current clinical thresholds. The study suggests that smaller declines in lung ...
PureTech Health (PRTC) announced results from ELEVATE IPF, a Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging trial evaluating deupirfenidone at two dose levels three ...
SAN DIEGO -- Two novel drugs improved lung function in idiopathic pulmonary fibrosis (IPF) in a pair of phase IIa trials, researchers reported here. In an open-label, single-arm trial of 46 patients ...
The Phase 2 study is a multi-center, randomized, partially double-blind, placebo- and active-controlled trial designed to evaluate the efficacy, safety, and pharmacokinetics of oral AK3280 in patients ...
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...
Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...
According to GRI Bio, the data shows that GRI-0621 directly impacts the core biology of IPF, with differentially expressed genes linked to key disease drivers supporting a mechanism consistent with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results